Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • 3BNC117: Phase I data

    The Rockefeller University, New York, N.Y. Product: 3BNC117 Business: Infectious Molecular target: CD4 Description: Humanized anti-CD4 binding site mAb Indication: Treat HIV-1 infection Endpoint: Safety; …

    Published on 4/20/2015
  • Anti-LINGO-1: Additional Phase II data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Product: Anti-LINGO-1 (BIIB033) Business: Neurology Molecular target: Leucine-rich repeat neuronal protein 1 (LINGO-1) Description: Antibody against leucine-rich repeat …

    Published on 4/20/2015
  • ECCS-50: Phase I data

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: ECCS-50 Business: Autoimmune Molecular target: NA Description: Autologous adipose tissue-derived stromal vascular fraction cells separated …

    Published on 4/20/2015
  • Epidiolex cannabidiol: Expanded access program additional data

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Product: Epidiolex cannabidiol Business: Neurology Molecular target: Cannabinoid receptors Description: Oral liquid formulation of cannabidiol, a …

    Published on 4/20/2015
  • Filgotinib: Phase IIb data

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Filgotinib (GLPG0634) Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1) Description: Janus kinase…

    Published on 4/20/2015
  • HaMPCs: Interim Phase IIb data

    Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Product: HaMPCs, ReJoin Business: Autoimmune Molecular target: NA Description: Autologous human adipose tissue-derived mesenchymal precursor cells …

    Published on 4/20/2015
  • Ibrance palbociclib: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Ibrance palbociclib (PD-0332991) Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent …

    Published on 4/20/2015
  • Imbruvica ibrutinib: Additional Phase II data

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Imbruvica ibrutinib (PCI-32765) Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description…

    Published on 4/20/2015
  • INO-3112: Preliminary Phase I/IIa data

    Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: INO-3112 Business: Cancer Molecular target: Human papillomavirus (HPV) antigens; Interleukin-12 (IL-12) Description: Combination of VGX-3100, a DNA-based…

    Published on 4/20/2015
  • Nefecon: Phase IIb data

    Archimedes Pharma Ltd., Reading, U.K. Pharmalink AB, Stockholm, Sweden Product: Nefecon (PL-56) Business: Renal Molecular target: NA Description: Enteric formulation of budesonide that downregulates the kidneys …

    Published on 4/20/2015
  • NM505: Pilot trial data

    MicroBiome Therapeutics LLC, Broomfield, Colo. Product: NM505 Business: Endocrine/Metabolic Molecular target: NA Description: Oral combination of metformin and a gastrointestinal microbiome modulator Indication: Treat …

    Published on 4/20/2015
  • Ozanimod: Additional Phase II data

    Receptos Inc. (NASDAQ:RCPT), San Diego, Calif. Product: Ozanimod (formerly RPC1063) Business: Autoimmune Molecular target: Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1) Description: Selective sphingosine-1-…

    Published on 4/20/2015
  • Reolysin: Additional Phase II data

    Andrus Reo Ltd., Moscow, Russia Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta Product: Reolysin Business: Cancer Molecular target: Not applicable Description: Formulation of human reovirus type 3 …

    Published on 4/20/2015
  • REP 2139-Ca: Phase II data

    Replicor Inc., Montreal, Quebec Product: REP 2139-Ca Business: Infectious Molecular target: NA Description: Nucleic acid polymer (NAP) Indication: Treat chronic HBV infection Endpoint: Safety, NAP-induced clearance of …

    Published on 4/20/2015
  • REP 2139-Ca: Phase II data

    Replicor Inc., Montreal, Quebec Product: REP 2139-Ca Business: Infectious Molecular target: NA Description: Nucleic acid polymer (NAP) Indication: Treat chronic HBV infection Endpoint: Safety, NAP-induced clearance of …

    Published on 4/20/2015
  • REP 2139-Ca: Phase II data

    Replicor Inc., Montreal, Quebec Product: REP 2139-Ca Business: Infectious Molecular target: NA Description: Nucleic acid polymer (NAP) Indication: Treat chronic HBV infection Endpoint: Safety, NAP-induced clearance of …

    Published on 4/20/2015
  • Rexista Oxycodone XR: Phase I data

    Intellipharmaceutics International Inc. (TSX:I; NASDAQ:IPCI), Toronto, Ontario Product: Rexista Oxycodone XR Business: Neurology Molecular target: Opioid receptor (OPR) Description: Controlled-release, abuse-deterrent …

    Published on 4/20/2015
  • Rexista Oxycodone XR: Phase I data

    Intellipharmaceutics International Inc. (TSX:I; NASDAQ:IPCI), Toronto, Ontario Product: Rexista Oxycodone XR Business: Neurology Molecular target: Opioid receptor (OPR) Description: Controlled-release, abuse-deterrent …

    Published on 4/20/2015
  • Rexista Oxycodone XR: Phase I data

    Intellipharmaceutics International Inc. (TSX:I; NASDAQ:IPCI), Toronto, Ontario Product: Rexista Oxycodone XR Business: Neurology Molecular target: Opioid receptor (OPR) Description: Controlled-release, abuse-deterrent …

    Published on 4/20/2015
  • Soliris eculizumab: Additional Phase II data

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: Soliris eculizumab Business: Transplant Molecular target: Complement 5 (C5) Description: Humanized mAb targeting complement 5 (C5) Indication: …

    Published on 4/20/2015
  • Tasquinimod: Development discontinued

    Active Biotech AB (SSE:ACTI), Lund, Sweden Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Tasquinimod (TASQ) (ABR-215050) Business: Cancer Molecular target: S100 calcium binding protein A9…

    Published on 4/20/2015
  • TT-034: Interim Phase I/IIa data

    Benitec Biopharma Ltd. (ASX:BLT), Sydney, Australia Product: TT-034 Business: Infectious Molecular target: NA Description: DNA-directed RNAi (ddRNAi) adenovirus vector (AAV) containing 3 RNAi elements Indication: Treat …

    Published on 4/20/2015
  • ABT-493: Preliminary Phase IIb data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-493 Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Next-generation HCV NS3…

    Published on 4/13/2015
  • ABT-530: Preliminary Phase IIb data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ABT-530 Business: Infectious Molecular target: HCV NS5A protein Description: Next-generation HCV NS5A protein inhibitor Indication: Treat chronic HCV genotype 1 infection …

    Published on 4/13/2015
  • Andexanet alfa: Additional Phase III data

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Product: Andexanet alfa (PRT4445, PRT064445) Business: Cardiovascular Molecular target: NA Description: Recombinant protein that reverses the …

    Published on 4/13/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993